Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Sine Reker Hadrup"'
Autor:
Sunil Kumar Saini, Staffan Holmberg-Thydén, Anne-Mette Bjerregaard, Ashwin Unnikrishnan, Simon Dorfmüller, Uwe Platzbecker, Irene Tirado-Gonzalez, Halvard Bönig, Daniel El Fassi, Kirsten Grønbæk, John Pimanda, Hind Medyouf, Sine Reker Hadrup
Publikováno v:
Saini, S K, Holmberg-Thydén, S, Bjerregaard, A M, Unnikrishnan, A, Dorfmüller, S, Platzbecker, U, Tirado-Gonzalez, I, Bönig, H, El Fassi, D, Grønbæk, K, Pimanda, J, Medyouf, H & Hadrup, S R 2022, ' Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies ', Leukemia, vol. 36, no. 11, pp. 2734-2738 . https://doi.org/10.1038/s41375-022-01705-y
Autor:
Sofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, Arianna Draghi, Marie Christine Wulff Westergaard, Signe Koggersbøl Skadborg, Nana Overgaard, Anders Bundgård Sørensen, Ida Svahn Rasmussen, Lars Vibe Andreasen, Christina Westmose Yde, Thomas Trolle, Christian Garde, Jens Friis-Nielsen, Nis Nørgaard, Dennis Christensen, Jens Vindahl Kringelum, Marco Donia, Sine Reker Hadrup, Inge Marie Svane
Publikováno v:
Oncoimmunology, 11
OncoImmunology, Vol 11, Iss 1 (2022)
Mork, S K, Kadivar, M, Bol, K F, Draghi, A, Westergaard, M C W, Skadborg, S K, Overgaard, N, Sorensen, A B, Rasmussen, I S, Andreasen, L V, Yde, C W, Trolle, T, Garde, C, Friis-Nielsen, J, Norgaard, N, Christensen, D, Kringelum, J V, Donia, M, Hadrup, S R & Svane, I M 2022, ' Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma ', OncoImmunology, vol. 11, no. 1, 2023255 . https://doi.org/10.1080/2162402X.2021.2023255
Oncoimmunology, 11, 1
Oncoimmunology
article-version (VoR) Version of Record
Mørk, S K, Kadivar, M, Bol, K F, Draghi, A, Westergaard, M C W, Skadborg, S K, Overgaard, N, Sørensen, A B, Rasmussen, I S, Andreasen, L V, Yde, C W, Trolle, T, Garde, C, Friis-Nielsen, J, Nørgaard, N, Christensen, D, Kringelum, J V, Donia, M, Hadrup, S R & Svane, I M 2022, ' Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma ', OncoImmunology, vol. 11, no. 1, 2023255 . https://doi.org/10.1080/2162402X.2021.2023255
OncoImmunology, Vol 11, Iss 1 (2022)
Mork, S K, Kadivar, M, Bol, K F, Draghi, A, Westergaard, M C W, Skadborg, S K, Overgaard, N, Sorensen, A B, Rasmussen, I S, Andreasen, L V, Yde, C W, Trolle, T, Garde, C, Friis-Nielsen, J, Norgaard, N, Christensen, D, Kringelum, J V, Donia, M, Hadrup, S R & Svane, I M 2022, ' Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma ', OncoImmunology, vol. 11, no. 1, 2023255 . https://doi.org/10.1080/2162402X.2021.2023255
Oncoimmunology, 11, 1
Oncoimmunology
article-version (VoR) Version of Record
Mørk, S K, Kadivar, M, Bol, K F, Draghi, A, Westergaard, M C W, Skadborg, S K, Overgaard, N, Sørensen, A B, Rasmussen, I S, Andreasen, L V, Yde, C W, Trolle, T, Garde, C, Friis-Nielsen, J, Nørgaard, N, Christensen, D, Kringelum, J V, Donia, M, Hadrup, S R & Svane, I M 2022, ' Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma ', OncoImmunology, vol. 11, no. 1, 2023255 . https://doi.org/10.1080/2162402X.2021.2023255
Contains fulltext : 249828.pdf (Publisher’s version ) (Open Access) The majority of neoantigens arise from unique mutations that are not shared between individual patients, making neoantigen-directed immunotherapy a fully personalized treatment app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd36dd614c206caacdb106b9bc536dc
http://hdl.handle.net/2066/249828
http://hdl.handle.net/2066/249828
Autor:
Beatrice Cavalluzzo, Angela Mauriello, Concetta Ragone, Carmen Manolio, Maria Lina Tornesello, Franco M. Buonaguro, Siri Amanda Tvingsholm, Sine Reker Hadrup, Maria Tagliamonte, Luigi Buonaguro
Publikováno v:
Cancers; Volume 14; Issue 1; Pages: 140
Cancers
Cavalluzzo, B, Mauriello, A, Ragone, C, Manolio, C, Tornesello, M L, Buonaguro, F M, Tvingsholm, S A, Hadrup, S R, Tagliamonte, M & Buonaguro, L 2022, ' Novel molecular targets for hepatocellular carcinoma ', Cancers, vol. 14, no. 1, 140 . https://doi.org/10.3390/cancers14010140
Cancers, Vol 14, Iss 140, p 140 (2022)
Cancers
Cavalluzzo, B, Mauriello, A, Ragone, C, Manolio, C, Tornesello, M L, Buonaguro, F M, Tvingsholm, S A, Hadrup, S R, Tagliamonte, M & Buonaguro, L 2022, ' Novel molecular targets for hepatocellular carcinoma ', Cancers, vol. 14, no. 1, 140 . https://doi.org/10.3390/cancers14010140
Cancers, Vol 14, Iss 140, p 140 (2022)
Simple Summary HCC is a disease with highly unmet medical needs. Specific target antigens for the development of active (vaccine) and/or passive (adoptive T-cell therapy) cancer immunotherapy strategies are needed. The aim of our study was to exploit
Autor:
Iben Spanggaard, Inge Marie Svane, Sine Reker Hadrup, Morten Hartvig Hansen, Vinicius Araujo Barbosa de Lima, Annie Borch, Arianna Draghi, Ulrik Lassen, Kristoffer Staal Rohrberg
Publikováno v:
Cytotherapy. 22:204-213
Background Immune checkpoint inhibitors (ICIs) have revolutionized the cancer therapeutic landscape and our perception of interactions between the immune system and tumor cells. Despite remarkable progress, disease relapse and primary resistance are
Autor:
Kristoffer Staal Rohrberg, Vinicius Araujo Barbosa de Lima, Inge Marie Svane, Ulrik Lassen, Sine Reker Hadrup, Iben Spanggaard, Morten Hartvig Hansen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Araujo B. de Lima, V, Hansen, M, Spanggaard, I, Rohrberg, K, Reker Hadrup, S, Lassen, U & Svane, I M 2021, ' Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types ', Frontiers in Oncology, vol. 11, 558248 . https://doi.org/10.3389/fonc.2021.558248
Frontiers in Oncology
Araujo B. de Lima, V, Hansen, M, Spanggaard, I, Rohrberg, K, Reker Hadrup, S, Lassen, U & Svane, I M 2021, ' Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types ', Frontiers in Oncology, vol. 11, 558248 . https://doi.org/10.3389/fonc.2021.558248
Frontiers in Oncology
Despite encouraging results with immune checkpoint inhibition (ICI), a large fraction of cancer patients still does not achieve clinical benefit. Finding predictive markers in the complexity of the tumor microenvironment is a challenging task and oft
Autor:
Simone Maarup, Ulrik Lassen, Benedikte Hasselbalch, Olga Østrup, Signe Koggersbøl Skadborg, Ian Law, David Scheie, Hans Skovgaard Poulsen, Sine Reker Hadrup, Arianna Draghi, Annie Borch, Inge Marie Svane, Jane Skjoeth-Rasmussen
Publikováno v:
Neuro Oncol
INTRODUCTION Glioblastoma is an aggressive brain tumor with a median survival of 14.6 months. We have no standard treatment for relapse and known options have limited effect. Novel treatments are necessary to improve survival and quality of life. MET
Autor:
Anne Ortved Gang, Kirsten Grønbæk, Mette K. Andersen, Marie Fredslund Breinholt, Mohammad Kadivar, Inge Marie Svane, Staffan Holmberg-Thydén, Sine Reker Hadrup, Lone Schejbel, Daniel El Fassi, Inge Høgh Dufva
Publikováno v:
Cancer immunology, immunotherapy : CII. 71(2)
Standard care for patients with high-risk myelodysplastic syndrome (MDS) is hypomethylating agents such as azacitidine (AZA), which can induce expression of methylated tumor-associated antigens and therefore potentiate immunotherapeutic targeting. In
Autor:
Sergio A. Quezada, Karl S. Peggs, Tariq Enver, Ehsan Ghorani, Javier Herrero, Benjamin M. Chain, Allan Hackshaw, S Kumar Saini, Charles Swanton, Sine Reker Hadrup, Nicholas McGranahan, Tom Lund, James L. Reading, M Vila De Mucha, Andrew Georgiou, A Ben Aissa, Roberto Salgado, Tahel Ronel, Rachel Rosenthal, Sofie Ramskov, M Robert de Massy, Andrew Furness, Virginia Turati, Jake Y. Henry, Imran Uddin
Publikováno v:
E-Poster Presentations.
Background Effective anti-tumour immunity requires cancer antigen expression, but persistent antigen exposure in chronic viral infections and autoimmunity has a detrimental effect on immune function. This is associated with a decline of early differe
Autor:
Cary Oberije, Monique C. de Jong, Dario Neri, Vincenzo Valentini, Giuliano Elia, Relinde I Y Lieverse, Yolande Lievens, Esther G.C. Troost, Evert J. Van Limbergen, Franziska Eckert, Charlotte Billiet, X. Geets, Ala Yaromina, Amir Abdollahi, P. Boisselier, Lizza E.L. Hendriks, Philippe Lambin, Crispin T. Hiley, Johan Bussink, Ludwig Dubois, David Pasquier, Christophe Dooms, Sine Reker Hadrup, Dirk De Ruysscher, Anne-Marie C. Dingemans
Publikováno v:
Lieverse, R I Y, Van Limbergen, E J, Oberije, C J G, Troost, E G C, Hadrup, S R, Dingemans, A-M C, Hendriks, L E L, Eckert, F, Hiley, C, Dooms, C, Lievens, Y, de Jong, M C, Bussink, J, Geets, X, Valentini, V, Elia, G, Neri, D, Billiet, C, Abdollahi, A, Pasquier, D, Boisselier, P, Yaromina, A, De Ruysscher, D, Dubois, L J & Lambin, P 2020, ' Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial ', BMC Cancer, vol. 20, no. 1, 557 . https://doi.org/10.1186/s12885-020-07055-1
BMC cancer
BMC Cancer, 20(1). BioMed Central Ltd.
BMC Cancer, 20, 1
BMC Cancer, 20(1):557. BioMed Central Ltd
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer, 20 (1)
BMC cancer, Vol. 20, no.1, p. 557 [1-10] (2020)
BMC Cancer, 20
BMC Cancer
BMC CANCER
BMC cancer
BMC Cancer, 20(1). BioMed Central Ltd.
BMC Cancer, 20, 1
BMC Cancer, 20(1):557. BioMed Central Ltd
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer, 20 (1)
BMC cancer, Vol. 20, no.1, p. 557 [1-10] (2020)
BMC Cancer, 20
BMC Cancer
BMC CANCER
Background About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone
Autor:
Ulrik Lassen, Benedikte Hasselbalch, Sine Reker Hadrup, Inge Marie Svane, Signe Koggersbøl Skadborg, Hans Skovgaard Poulsen, Arianna Draghi, Annie Borch, Simone Maarup
Publikováno v:
Neuro Oncol
Glioblastoma (GBM) is an aggressive brain tumor with a dismal prognosis. Salvage neurosurgical resection is performed if possible and GBM patients are hereafter treated with Stupp’s regime as standard treatment in the primary setting. However, afte